The diversity of clinical, hematological and genetic features among patients with acute
myeloid leukemia (AML) has been recognized for many decades. However, during recent …

BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall
survival, lower rates or short complete remission and extramedullary invasion but the results …

The aims of this study were to investigate the frequency and prognostic relevance of CD56
expression in patients with acute myeloid leukemia (AML) and to compare the importance of …

BACKGROUND AND OBJECTIVES. CD56 antigen expression has been reported in several
hematologic malignancies. In acute myeloid leukemia (AML) M2 with t (8; 21) and acute …

Acute myeloid leukemia (AML) is a heterogeneous group of disorders with distinct
characteristics and prognoses. Although cytogenetic changes and gene mutations are …

Abstract Abstract 4880 Background: The CD56 is a neural cell adhesion molecule (N-CAM)
expressed in natural killer cells. CD56 expression on the surface of leukemic cells in acute …

Abstract CD56 antigen, a 200–220 kDa cell surface glycoprotein, identified as an isoform of
the neural adhesion molecules (NCAM), has been found frequently expressed in several …

Background. CD56 expression was extensively investigated in cases of acute leukemia.
Many studies associated it with short overall survival, unfavorable outcome, lower rates or …

A number of clinical and biological factors in acute myeloid leukemia (AML) have been used
to predict the response to induction treatment or the likelihood of relapse …

CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic
phenotype and resistance to induction therapy but no inferior survival after risk-adapted …